<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Autologous TumorGraft3D Co-Culture Screen

Screen enrollment closes on May 31, 2024. Enroll Now

The 1st Autologous TumorGraft3D Co-Culture Screen Available

Champions' Autologous TumorGraft3D Co-Culture Screen offers 13 unique 3D models co-cultured with their matched tumor-infiltrating lymphocytes (TILs). This list of models has been curated by oncology experts to assess your immuno-oncology agents of any class or any therapeutic that affects or benefits from the immune system interaction with the tumor. 

Autologous TumorGraft3D Co-Culture Workflow

The Autologous TumorGraft3D Co-Culture Platform

Champions' TumorGraft3D models are 3D, low passage, ex-vivo models derived from our deeply characterized and clinically annotated proprietary PDX models, representative of the heterogeneity of the patient population.

The autologous TumorGraft3D co-culture platform leverages a matrix-free assay, using indication-specific proprietary media to allow for TumorGraft3D formation and retention of patients’ key molecular and phenotypical features, with matched patient-derived TILs added in culture after model formation.

TumorGraft3D’s versatility and clinical relevance, along with their molecular characterization, together with patient-matched TILs, make this the ideal 3D ex vivo co-culture assay to:

  • measure immuno-oncology agent efficacy and lymphocyte recruiting/activating effects,
  • unravel the complexities of tumor biology and the crucial interactions within the tumor microenvironment,
  • evaluate synergistic combination therapies to advance your drug development through data-driven decisions.

Screen Features

  • Enrollment Open until May 31st, 2024
  • 1st autologous 3D tumor co-culture screen available on the market featuring 13 unique models 
  • 50% OFF of a standard of care arm (selected by Champions)
  • Available endpoints:
    • High-content imaging analysis to evaluate tumor killing and lymphocyte infiltration.
    • DRUG-seq, a fully plate-based RNA-seq analysis that uses limited starting material and provides a dynamic view that captures the immediate and prolonged gene expression changes following drug administration, enabling the study of mechanisms of action and biomarker discovery.

    • FlowHT, a quantitative plate-based flow cytometry analysis optimized specifically for the TumorGraft3D platform that enables scalability of ex vivo conditions and robust results. FlowHT applications are:

      • Deconvolution of cellular and phenotypical changes across multiple cell types​
      • Identify immune cell marker expression/activation on PBMCs ​
      • Investigate the mechanism of tumor cell death induced by immune cells​
      • Evaluate ADCC effects or to identify antigens of interest

Example of TumorGraft3D Model Characterization
CTG3D-3631 characterization
Autologous TumorGraft3D Co-Culture
Co-culture image

Enroll in the Autologous TumorGraft3D Co-Culture Screen